\
&
Contact us
\
&
Contact us
About the programme
Specific Objective 3 – Cybersecurity and Trust aims to raise the level of protection of citizens and organisations and improving the security of digital products and services throughout the whole supply chain as a fundamental building block of the EU’s digital transformation.
The majority of cybersecurity related activities will funded by the Cybersecurity Industrial, Technology and Research Competence Centre (ECCC). For the 2025-2027 period, Specific Objective 3 focuses on the following activities:
marie.timmermann@fwo.be
+32 2 550 15 59
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Security Digital, Industry & Space Cybersecurity
The NIS Cooperation Group has launched a survey to collect feedback aimed at guiding the future steps towards implementing quantum-safe cryptography in Europe. This initiative follows the release of the "Coordinated Implementation Roadmap for the Transition to Post-Quantum Cryptography (PQC)". Quantum computing poses significant challenges to data... read more
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
